Vaccine Adjuvants Market Outlook

Global Vaccine Adjuvants Market Size - By Product Type, By Route of Administration, By Disease Type, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2035

Published: Jul-2026	Report ID: HLCA2632	Pages: 1 - 250	Formats^*:
Category : Healthcare

According to SPER Market Research, the Global Vaccine Adjuvants Market is estimated to reach USD 2.66 billion by 2035 with a CAGR 6.74%.

Introduction and Overview

The report includes an in-depth analysis of the Global Vaccine Adjuvants Market, including market size and trends, product mix, Applications, and supplier analysis.

The global Vaccine Adjuvants Market was valued at USD 1.39 billion in 2025 and is expected to reach USD 2.66 billion by 2035, registering a CAGR of 6.74% during the forecast period. Vaccine adjuvants enhance immune system stimulation, improving vaccine effectiveness while reducing the amount of antigen required, making vaccines more efficient and cost-effective. The increasing prevalence of cancer and infectious diseases, including HPV, HIV, and tuberculosis, is driving demand for advanced vaccine adjuvants. Additionally, the growing emphasis on achieving long-lasting immunity against existing and emerging diseases is accelerating their adoption. By strengthening immune responses and reducing the number of antigen doses needed, adjuvants improve vaccine performance, support broader immunization efforts, and contribute to the development of more effective and affordable vaccination programs worldwide.

By Product Type:

The particulate adjuvants segment held the largest share in 2025, driven by the rising demand for highly effective vaccines against infectious diseases. Particulate adjuvants enhance immune responses, improving vaccine efficacy and supporting stronger, longer-lasting protection. Their ability to efficiently deliver antigens to immune cells has increased their importance in modern vaccine development. Furthermore, advancements in materials science and drug delivery technologies have enabled the development of innovative particulate adjuvants with improved antigen encapsulation and targeted delivery capabilities. These benefits continue to accelerate their adoption across a wide range of preventive and therapeutic vaccines.

By Route of Administration:

The intramuscular segment dominated the market in 2025 due to its ability to induce strong and long-lasting immune responses. Intramuscular administration enhances the effectiveness of adjuvanted vaccines, making it a preferred route for protecting populations against infectious diseases. Growing global immunization initiatives and increased emphasis on effective vaccination programs have further supported its adoption. Additionally, intramuscular delivery ensures efficient antigen uptake and a robust immune response, improving vaccine performance. Its proven safety, reliability, and compatibility with a wide range of vaccine formulations continue to drive its widespread use in public health and immunization programs.

By Disease Type:

The infectious diseases segment dominated the market in 2025, driven by the rising global burden of viral, bacterial, and parasitic infections. Increasing demand for effective vaccines against diseases such as COVID-19, influenza, tuberculosis, and emerging pathogens has accelerated the adoption of vaccine adjuvants. Advances in adjuvant technologies, including liposomes, nanoparticles, and other particulate systems, have significantly improved vaccine efficacy by enhancing immune responses. Additionally, continued investment in vaccine research and the growing focus on developing targeted, long-lasting immunity against infectious diseases are expected to further support the segment’s growth.

Regional Insights:

The U.S. vaccine adjuvants market is expected to witness strong growth, supported by extensive investments in vaccine research and public health initiatives. Government organizations and research institutions continue to advance adjuvant development for infectious disease prevention. In addition, collaborations between pharmaceutical companies, universities, and biotechnology firms are accelerating innovation in adjuvant technologies and improving existing formulations. These partnerships are fostering the development of more effective, accessible, and cost-efficient vaccine adjuvants for both preventive and therapeutic applications.

Market Competitive Landscape:

The Global Vaccine Adjuvants Market is highly consolidated Some of the market key players are Agenus, Allergy Therapeutics, Aurorium, Brenntag Biosector, Croda International, CSL Limited, Dynavax Technologies Corporation, EuBiologics, GSK plc, Merck KGaA, Novavax, OZ Biosciences, Riboxx GmbH, and Seppic.

Recent Developments:

In September 2025, Novavax expanded its partnership with Sanofi, granting broader rights to use its Matrix-M adjuvant in pandemic influenza vaccine development, with the agreement including milestone payments and royalty opportunities for future products.
In July 2025, GSK plc announced that the U.S. FDA accepted its application to expand the indication of its adjuvanted Arexvy RSV vaccine to include at-risk adults aged 18–49, with a regulatory decision expected in the first half of 2026.

Scope of the report:

Report Metric Details

Market size available for the years 2022-2035

Base year considered 2025

Forecast Period 2026-2035

Segments Covered By Product Type, By Route of Administration, By Disease Type, By Application-

Regions Covered North America, Latin America, Asia-Pacific,

Europe, and Middle East & Africa

Companies Covered Agenus, Allergy Therapeutics, Aurorium, Brenntag Biosector, Croda International, CSL Limited, Dynavax Technologies Corporation, EuBiologics, GSK plc, Merck KGaA, Novavax, OZ Biosciences, Riboxx GmbH, and Seppic.

Key Topics Covered in the Report

Global Vaccine Adjuvants Market Size (FY’2022-FY’2035)
Overview of Global Vaccine Adjuvants Market
Segmentation of Global Vaccine Adjuvants Market by Product Type (Adjuvant emulsions, Pathogen components, Saponin-based adjuvants, Particulate adjuvants, Other product types)
Segmentation of Global Vaccine Adjuvants Market by Route of Administration (Intramuscular, Subcutaneous, Oral, Other routes of administration)
Segmentation of Global Vaccine Adjuvants Market by Disease Type (Infectious diseases, Cancer, Other diseases)
Segmentation of Global Vaccine Adjuvants Market by Application (Human vaccines, Veterinary vaccines)
Statistical Snap of Global Vaccine Adjuvants Market
Expansion Analysis of Global Vaccine Adjuvants Market
Problems and Obstacles in Global Vaccine Adjuvants Market
Competitive Landscape in the Global Vaccine Adjuvants Market
Details on Current Investment in Global Vaccine Adjuvants Market
Competitive Analysis of Global Vaccine Adjuvants Market
Prominent Players in the Global Vaccine Adjuvants Market
SWOT Analysis of Global Vaccine Adjuvants Market
Global Vaccine Adjuvants Market Future Outlook and Projections (FY’2026-FY’2035)
Recommendations from Analyst

1. Introduction

1.1 Scope of the report
1.2 Market segment analysis

2. Research Methodology

2.1 Research data source

2.1.1 Secondary Data
2.1.2 Primary Data
2.1.3 SPER’s internal Database
2.1.4 Primary insight from KOL’s

2.2 Market size estimation

2.2.1 Top-down and Bottom-up approach

2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1 Driver, Restraint, Opportunity and Challenges analysis

4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges

5. Market variable and outlook

5.1 SWOT Analysis

5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats

5.2 PESTEL Analysis

5.2.1 Political Landscape
5.2.2 Economic Landscape
5.2.3 Social Landscape
5.2.4 Technological Landscape
5.2.5 Environmental Landscape
5.2.6 Legal Landscape

5.3 PORTER’s Five Forces
5.4 Heat Map Analysis

6. Competitive Landscape

6.1. Global Vaccine Adjuvants Market Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vaccine Adjuvants Market

7. Global Vaccine Adjuvants Market, By Product Type, (USD Million) 2022-2035

7.1 Adjuvant emulsions
7.2 Pathogen components
7.3 Saponin-based adjuvants
7.4 Particulate adjuvants
7.5 Other product types

8. Global Vaccine Adjuvants Market, By Route of Administration, (USD Million) 2022-2035

8.1 Intramuscular
8.2 Subcutaneous
8.3 Oral
8.4 Other routes of administration

9. Global Vaccine Adjuvants Market, By Disease Type, (USD Million) 2022-2035

9.1 Infectious diseases
9.2 Cancer
9.3 Other diseases

10. Global Vaccine Adjuvants Market, By Application, (USD Million) 2022-2035

10.1 Human vaccines
10.2 Veterinary vaccines

11. Global Vaccine Adjuvants Market, (USD Million) 2022-2035

11.1 Global Vaccine Adjuvants Market Size and Market Share

12. Global Vaccine Adjuvants Market, By Region, (USD Million) 2022-2035

12.1 Asia-Pacific

12.1.1 Australia
12.1.2 China
12.1.3 India
12.1.4 Japan
12.1.5 South Korea
12.1.6 Rest of Asia-Pacific

12.2 Europe

12.2.1 France
12.2.2 Germany
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
12.2.6 Rest of Europe

12.3 Middle East and Africa

12.3.1 Kingdom of Saudi Arabia
12.3.2 United Arab Emirates
12.3.3 Qatar
12.3.4 South Africa
12.3.5 Egypt
12.3.6 Morocco
12.3.7 Nigeria
12.3.8 Rest of Middle-East and Africa

12.4 North America

12.4.1 Canada
12.4.2 Mexico
12.4.3 United States

12.5 Latin America

12.5.1 Argentina
12.5.2 Brazil
12.5.3 Rest of America

13. Company Profile

13.1 Agenus

13.1.1 Company details
13.1.2 Financial outlook
13.1.3 Product summary
13.1.4 Recent developments

13.2 Allergy Therapeutics

13.2.1 Company details
13.2.2 Financial outlook
13.2.3 Product summary
13.2.4 Recent developments

13.3 Aurorium

13.3.1 Company details
13.3.2 Financial outlook
13.3.3 Product summary
13.3.4 Recent developments

13.4 Brenntag Biosector

13.4.1 Company details
13.4.2 Financial outlook
13.4.3 Product summary
13.4.4 Recent developments

13.5 Croda International

13.5.1 Company details
13.5.2 Financial outlook
13.5.3 Product summary
13.5.4 Recent developments

13.6 CSL Limited

13.6.1 Company details
13.6.2 Financial outlook
13.6.3 Product summary
13.6.4 Recent developments

13.7 Dynavax Technologies Corporation

13.7.1 Company details
13.7.2 Financial outlook
13.7.3 Product summary
13.7.4 Recent developments

13.8 EuBiologics

13.8.1 Company details
13.8.2 Financial outlook
13.8.3 Product summary
13.8.4 Recent developments

13.9 GSK plc

13.9.1 Company details
13.9.2 Financial outlook
13.9.3 Product summary
13.9.4 Recent developments

13.10 Merck KGaA

13.10.1 Company details
13.10.2 Financial outlook
13.10.3 Product summary
13.10.4 Recent developments

13.11 Novavax

13.11.1 Company details
13.11.2 Financial outlook
13.11.3 Product summary
13.11.4 Recent developments

13.12 OZ Biosciences

13.12.1 Company details
13.12.2 Financial outlook
13.12.3 Product summary
13.12.4 Recent developments

13.13 Riboxx GmbH

13.13.1 Company details
13.13.2 Financial outlook
13.13.3 Product summary
13.13.4 Recent developments

13.14 Seppic

13.14.1 Company details
13.14.2 Financial outlook
13.14.3 Product summary
13.14.4 Recent developments

13.15 Others

14. Conclusion

15. List Of Abbreviations

16. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1